Literature DB >> 27220778

High glucose-induced fibronectin upregulation in cultured mesangial cells involves caveolin-1-dependent RhoA-GTP activation via Src kinase.

Yongfu Lu1, Lihong Tang2, Yiqiao Li3, Qiang He3.   

Abstract

Increasing evidence indicates that diabetes-mediated renal interstitial fibrosis through extracellular matrix (ECM) protein accumulation is an important event in the development of diabetic kidney disease (DKD), however, the underlying mechanism remains unclear. In the current study, it was observed that high levels of glucose (HG) time‑ and dose-dependently increased the production of the ECM protein, fibronectin (FN), in primary rat mesangial cells. Inhibition of the Rho pathway blocked HG‑induced FN upregulation. HG‑induced RhoA activation was prevented by inhibiting caveolae with filipin III or caveolin‑1 siRNA and rescued by exogenous caveolin‑1. HG also increased caveolin-1/Src association and activated Src kinase, whereas the inhibition of Src blocked RhoA activation and FN upregulation. Src-mediated phosphorylation of caveolin‑1 on Y14 has also been implicated in signaling responses. Overexpression of the nonphosphorylatable caveolin‑1 Y14A mutant prevented the HG‑induced RhoA activation and FN upregulation. In conclusion, HG‑induced FN upregulation requires caveolae and caveolin‑1 to interact with RhoA and Src kinases. Interference with Src/caveolin-1/RhoA signaling may provide novel mechanistic targets for the treatment of DKD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27220778     DOI: 10.3892/mmr.2016.5312

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

Review 1.  Src family kinases in chronic kidney disease.

Authors:  Jun Wang; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2017-06-14

Review 2.  Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?

Authors:  Richard Van Krieken; Joan C Krepinsky
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

3.  Src Activation Aggravates Podocyte Injury in Diabetic Nephropathy via Suppression of FUNDC1-Mediated Mitophagy.

Authors:  Ting Zheng; Han-Yu Wang; Yang Chen; Xiao Chen; Zi-Ling Wu; Qin-Yu Hu; Hui Sun
Journal:  Front Pharmacol       Date:  2022-05-09       Impact factor: 5.988

4.  Regulation of transforming growth factor β-mediated epithelial-mesenchymal transition of lens epithelial cells by c-Src kinase under high glucose conditions.

Authors:  Zhi-Hua Han; Fang Wang; Fu-Lei Wang; Qi Liu; Jian Zhou
Journal:  Exp Ther Med       Date:  2018-06-22       Impact factor: 2.751

5.  Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate.

Authors:  Lili Qin; Wenjun Qin; Jianfei Wang; Lin Lin
Journal:  Exp Ther Med       Date:  2017-09-12       Impact factor: 2.447

6.  Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy.

Authors:  Na Du; Zhiping Xu; Mingyue Gao; Peng Liu; Bo Sun; Xia Cao
Journal:  Drug Des Devel Ther       Date:  2018-10-18       Impact factor: 4.162

7.  DMP-1 attenuates oxidative stress and inhibits TGF-β activation in rats with diabetic kidney disease.

Authors:  Na Du; Shunan Liu; Chongshuang Cui; Mo Zhang; Jibin Jia; Xia Cao
Journal:  Ren Fail       Date:  2016-11-23       Impact factor: 2.606

8.  Influence of high glucose on mesangial cell-derived exosome composition, secretion and cell communication.

Authors:  Antônio da Silva Novaes; Fernanda Teixeira Borges; Edgar Maquigussa; Vanessa Araújo Varela; Marcos Vinicios Salles Dias; Mirian Aparecida Boim
Journal:  Sci Rep       Date:  2019-04-18       Impact factor: 4.379

9.  miR-154-5p Affects the TGFβ1/Smad3 Pathway on the Fibrosis of Diabetic Kidney Disease via Binding E3 Ubiquitin Ligase Smurf1.

Authors:  Che Bian; Zhilin Luan; Haibo Zhang; Ruijing Zhang; Jing Gao; Yuxia Wang; Jia Li; Huiwen Ren
Journal:  Oxid Med Cell Longev       Date:  2022-01-27       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.